Search Results
Aug 19, 2026, 13:12 ET AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky
alleges Aardvark Therapeutics made materially false or misleading statements regarding ARD-101's safety and tolerability, including claims that the drug was approximately 99% gut-restricted with limited systemic absorption and no serious adverse events, during the Class Period. When the voluntary Phase
More news about: Levi & Korsinsky, LLP
Aug 19, 2026, 12:40 ET SandboxAQ Makes AQCat Generally Available on Claude for High-Throughput Catalyst Screening
Anything that helps researchers reduce uncertainty is incredibly valuable, and SandboxAQ's MCP tools in Claude do that for both materials science and drug discovery."AQCat is available today through Claude Science, on SandboxAQ's
More news about: SandboxAQ
Aug 19, 2026, 11:53 ET SandboxAQ Launches AQPotency, Bringing Ultrafast Virtual Screening to Drug Discovery Without a Solved Protein Structure
well a potential drug will work, now available on Claude via Model Context Protocol (MCP). For any disease target, AQPotency scores how strongly candidate molecules are likely to act on it, and it does this without the expensive, time-consuming lab work that older methods depend on. Drug discovery teams
More news about: SandboxAQ
Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight
Therapies: Pharmaceutical and biotechnology companies are actively developing novel immunotherapies, targeted therapies, bispecific antibodies, antibody-drug conjugates (ADCs), cell therapies, and combination regimens aimed at restoring antitumor immune responses in refractory patients.Growing
More news about: DelveInsight Business Research, LLP
Aug 19, 2026, 09:41 ET Sensorium Therapeutics Announces SNTX-2643 Phase 1a Data to Be Presented at Psych Congress 2026
its proprietary SensAI discovery platform, which integrates chemistry, pharmacology, behavioral science, and neuroscience, to systematically predict drug candidates with differentiated mechanisms of action.Founded by researchers from Harvard and Massachusetts General Hospital, Sensorium is advancing
More news about: Sensorium Therapeutics
Aug 19, 2026, 09:14 ET XtalPi Holdings Announces 2026 Interim Results
business model centered on Drug Discovery Solutions and AI4S Intelligent Solutions (AI4S Infrastructure), combining recurring cash flow with the potential for asset value realization.Drug Discovery Solutions are built around the Group's AI-driven drug discovery capabilities and
More news about: XtalPi Holdings Limited
Aug 19, 2026, 09:04 ET Superbrewed Food Launches Thryvia™, the First Shelf-Stable Protein-Derived Postbiotic for Digestive and Immune Health Formulations
Clostridium tyrobutyricum (strain ASM19) and is shelf-stable at room temperature. The ingredient received a "No Questions" letter from the U.S. Food and Drug Administration under GRAS Notice GRN 1129.About Superbrewed Food, Inc.Superbrewed Food is a nutrition and health company focused
More news about: Superbrewed Food Inc.
Aug 19, 2026, 09:00 ET Allure Beauty Concepts Converts Scottsdale Facility to FDA-Registered OTC Manufacturing Site
ingredient at a monograph-specified concentration, carries a Drug Facts panel, and makes a treatment claim — such as blocking UV rays, treating acne, controlling dandruff, or preventing cavities — it is legally an OTC drug and must be manufactured under drug cGMP (21 CFR 211). That standard requires an OTC-qualified
More news about: Allure Beauty Concepts
Aug 19, 2026, 09:00 ET EndoCyclic Therapeutics Nominated for 2026 Prix Galien USA Award
and CEO of Merck & Co., Inc.The nomination follows a significant milestone for EndoCyclic, with FDA clearance of the Investigational New Drug (IND) application for ENDO-205, a first-in-class, non-hormonal peptide therapeutic designed to target and eliminate endometriosis lesions rather than
More news about: EndoCyclic Therapeutics
Aug 19, 2026, 09:00 ET ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights
/PRNewswire/ -- ZEISS Medical Technology, one of the world's leading medical technology companies, today announced the 510k clearance from the U.S. Food and Drug Administration (FDA) for ZEISS CLINIC 3601. An all-in-one cloud and browser-based software solution, ZEISS CLINIC 360 combines diagnostic
More news about: Carl Zeiss Meditec AG
Aug 19, 2026, 09:00 ET ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights
/PRNewswire/ -- ZEISS Medical Technology, one of the world's leading medical technology companies, today announced the 510k clearance from the U.S. Food and Drug Administration (FDA) for ZEISS CLINIC 3601. An all-in-one cloud and browser-based software solution, ZEISS CLINIC 360 combines diagnostic
More news about: Carl Zeiss Meditec AG
Aug 19, 2026, 08:32 ET Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Next Generation Flow Cytometry (NGF) assay for MM MRD served as the analytical method for the pivotal efficacy endpoint supporting the U.S. Food and Drug Administration's (FDA) accelerated approval of Bristol Myers Squibb's
More news about: Hematogenix
Aug 19, 2026, 08:30 ET SFA THERAPEUTICS, INC. ANNOUNCES EXECUTIVE ORGANIZATIONAL CHANGES
with outstanding results, SFA Therapeutics, Inc. is now positioning itself for the commercial development of SFA-002D, a drug that has the potential to reset the immune system. This drug has shown significant results in the treatment of psoriasis, as a proof of concept for application of the platform in
More news about: SFA Therapeutics, Inc.
Aug 19, 2026, 08:00 ET DeepCyte Launches World's First Single-Cell Mechanistic Toxicity Atlas as Enterprise Pharma Pilots Advance
/PRNewswire/ -- DeepCyte Inc., a techbio company building AI toxicology tools for drug development, today announced the launch of DeeTox Atlas™, the world's first single-cell metabolomic reference atlas of drug toxicity mechanisms. Enterprise pilot programs with global pharmaceutical companies
More news about: DeepCyte
Aug 19, 2026, 08:00 ET DeepCyte Launches World's First Single-Cell Mechanistic Toxicity Atlas as Enterprise Pharma Pilots Advance
/PRNewswire/ -- DeepCyte Inc., a techbio company building AI toxicology tools for drug development, today announced the launch of DeeTox Atlas™, the world's first single-cell metabolomic reference atlas of drug toxicity mechanisms. Enterprise pilot programs with global pharmaceutical companies
More news about: DeepCyte
Aug 19, 2026, 08:00 ET Empatica Receives FDA Clearance for Parkinson's Monitoring
wearable technology, today announced that the Empatica Health Monitoring Platform for Parkinson's has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The clearance builds on Empatica's 2025 acquisition of PKG Health and expands the company's clinical-grade monitoring platform
More news about: Empatica, Inc.
Aug 19, 2026, 07:55 ET /C O R R E C T I O N -- Vector Sciences & Therapeutics/
business."A Global Partner Across the Drug Development LifecycleHeadquartered in Mequon, Wisconsin, with a global reach spanning European and American markets, Verlytix operates across four core areas of business:Injectable Drug Product Testing, including assay/potency,
More news about: Vector Sciences & Therapeutics
Aug 19, 2026, 07:46 ET Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum
reported revenue of RMB15.46 billion. Drug sales revenue was RMB13.95 billion, representing a year-over-year increase of 1.87%. Innovative drug sales increased by 16.38% year-over-year and accounted for 63.16% of total drug sales, with non-oncology innovative drug sales increasing by 73.97% year-over-year
More news about: Hengrui Pharma
Aug 19, 2026, 07:45 ET IU Health launches theranostics center of excellence to expand personalized treatments for patients with cancer
Medicine and Vera Bradley Professor of Oncology at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center. "From scientific discovery and drug development to manufacturing, clinical trials and patient care delivery, Indiana is on track to become one of the world's leading centers for theranostics
More news about: Indiana University Health, Inc.
Aug 19, 2026, 07:37 ET How People Consume Cannabis May Signal Risk for Heavy Use and Addiction
naturally cluster, the researchers analyzed data from 17,732 adults who reported using cannabis in the past month on the 2022–2023 National Survey on Drug Use and Health. The authors used a statistical approach that grouped participants based on their reported patterns.The results also revealed
More news about: NYU Grossman School of Medicine and NYU Langone Health
Aug 19, 2026, 07:00 ET Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
pre-clinical or clinical trial; regulatory action with respect to CG-100, Aramchol or any other medical device or product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization,
More news about: Galmed Pharmaceuticals Ltd.
Aug 19, 2026, 06:00 ET IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding and lack of brain penetrance intended to maximize its therapeutic window, and favorable drug-like properties to enable rational combinations with IDE397, pan-RAS inhibitors, KRAS-mutant specific therapies, and IDEAYA's CDKN2A lead molecule.
More news about: IDEAYA Biosciences, Inc.
Aug 19, 2026, 05:50 ET BioArctic and Mesenkia enter oncology research collaboration
treatment possibilities for patients with a very high unmet medical need.Under the agreement, BioArctic will be responsible for generating a novel drug candidate by combining its BrainTransporter technology with Mesenkia's antibody. BioArctic and Mesenkia thereafter plan to perform preclinical studies
More news about: BioArctic
Aug 19, 2026, 05:42 ET BioArctic and Mesenkia enter oncology research collaboration
treatment possibilities for patients with a very high unmet medical need.Under the agreement, BioArctic will be responsible for generating a novel drug candidate by combining its BrainTransporter technology with Mesenkia's antibody. BioArctic and Mesenkia thereafter plan to perform preclinical studies
More news about: BioArctic
Aug 19, 2026, 05:00 ET NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product
BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORROY's 68Ga-NYM096, a potential radiopharmaceutical
More news about: Norroy Bioscience Co., Ltd.